Table 3.
Indications for warfarin chemoprophylaxis (n = 1,568)
| Chemoprophylaxis | THA | TKA | UKA | Total |
|---|---|---|---|---|
| Aspirin | 697 (79 %) | 389 (60.3 %) | 29 (80 %) | 1,115 (71.1 %) |
| Warfarin | 180 (20 %) | 239 (37 %) | 7 (20 %) | 426 (27.1 %) |
| Enoxaparin to warfarin | 6 (0.7 %) | 11 (1.7 %) | 0 | 17 (1 %) |
| VCF | 4 (0.5 %) | 6 (0.9 %) | 0 | 10 (0.6 %) |
| Indication for warfarin chemoprophylaxis | ||||
| Obesity | 44 (5 %) | 76 (11.8 %) | 0 | 120 (7.7 %) |
| Bilateral procedure | 2 (0.2 %) | 54 (8.4 %) | 3 (8.3 %)a | 59 (3.8 %) |
| Preexisting cardiac/CNS disorders | 18 (2 %) | 25 (3.9 %) | 2 (5.5 %) | 45 (2.9 %) |
| History of VTE or hypercoagulable disorder | 37 (4.2 %) | 25 (3.9 %) | 0 | 62 (4 %) |
| Aspirin allergy or intolerance | 12 (1.4 %) | 25 (3.9 %) | 0 | 37 (2.4 %) |
| Recent or current malignancy | 13 (1.5 %) | 11 (1.7 %) | 1 (2.8 %) | 25 (1.6 %) |
| Slow mobilisation | 47 (5.5 %) | 18 (2.8 %) | 0 | 65 (4.1 %) |
| Multifactorial | 6 (0.7 %) | 5 (0.8 %) | 1 (2.8 %) | 12 (0.8 %) |
| Patient request | 1 (0.1 %) | 0 | 0 | 1 (0.06 %) |
THA total hip arthroplasty, TKA total knee arthroplasty, UKA unicompartmental knee arthroplasty, n number of patients, % percentage of patients, VCF vena cava filter, VTE venous thromboembolism
aA patient had a bilateral knee replacement consisting of a TKA and a contralateral UKA